Exchange: NYSE·Updated 02:45 PM EST
BAX logo

BAX Baxter International Inc.

$26.18
$0.42
(1.63%)
Today
Reported EarningsOct 29
Mkt Cap$13.33B
Vol1.96M

About BAX

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment sells connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment focuses on the sales of specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.
35

Bearish Sentiment

How do you feel about BAX?

Yi_YandH
$BAX $FMS $ICU If #275-#300 patient enrollee in Neutralize-AKI is announced @ Q3 ER along with the below mentioned milestones, then $10 PPS is very, very possible. Don’t be eating government cheese living in a van down by the river. Be a motivational speaker on this bard movin’ on up.
3
AdamBrennan2
baxter $BAX screens as the cheapest name in this group of medical device makers on sales, at 1.1x against a peer median of 4.2x it makes the hospital basics: renal care, iv drugs and the pumps that deliver them, sold to hospitals and clinics but forward earnings are expected to shrink 5.1% while every other peer is expected to grow, so the discount has a reason to me this is a cheap price on a business that has to prove it can grow earnings again. what am i missing here? $ABT $DHR $SYK $ISRG
KryptonResearch14
$BAX Baxter's long contract book is shrinking while sales grow. Transaction price allocated to remaining performance obligations on executed contracts over one year was 7.58 billion dollars at Sep 30, down from 8.50 billion at year end and 8.87 billion at Mar 31. Only about 10 percent of that is scheduled to convert in the rest of 2026, with 25 percent in 2027. Medical Products and Therapies, where these contracts sit, did 2,102 million dollars of sales in Q3.
filecrux
$BAX Can Baxter reach its raised $2.05-$2.15 adjusted EPS guide after Q3 adjusted EPS fell 16%? 🏢 Baxter, the maker of hospital IV solutions, infusion pumps and smart beds, had a market value of about $13.16B at the October 28, 2026 close of $25.46 (16:00 ET), and it lifted its 2026 adjusted EPS floor to $2.05 from $1.95 📉 Q3 adjusted EPS fell 16% to $0.58 from $0.69 because the adjusted tax rate jumped to 18.3% from 5.1%, while adjusted pre-tax income held flat at $371M against $372M ⚠️ The bear case is that adjusted operating income rose only 2% to $432M on 5% sales growth, as unallocated corporate costs climbed to $156M from $115M 📅 Next: Baxter presents at the J.P. Morgan Healthcare Conference, January 11-13, 2027; the $0.01 quarterly dividend is payable January 4, 2027 Source: SEC 8-K and Q3 release, Oct 29, 2026
shoc24
$BAX reported earnings before the open: adjusted EPS of $0.58 vs. $0.52 estimated, a beat of 12.0%. I used Stock Meadow to review the results.
StocktwitsEarnings
$BAX Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.58 down -15.94% YoY • Reported revenue of $2.98B up 4.97% YoY • Baxter raised FY 2026 reported sales growth guidance to 4% to 5%, organic sales growth to 3% to 4%, and adjusted diluted EPS to $2.05 to $2.15.
shoc24
$BAX reports earnings tomorrow before the open. I’m bullish heading into the report: BAX has beaten EPS estimates in 6 of its last 8 reports, according to Stock Meadow.

Advertisement|Remove ads.